Centessa Pharmaceuticals plc (CNTA)

Market Cap	882.06M
Revenue (ttm)	6.85M
Net Income (ttm)	-151.09M
Shares Out	98.77M
EPS (ttm)	-1.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	286,149
Open	9.26
Previous Close	9.46
Day's Range	8.90 - 9.39
52-Week Range	3.96 - 12.45
Beta	1.39
Analysts	Buy
Price Target	10.00 (+11.98%)
Earnings Date	May 10, 2024

About CNTA

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 28, 2021
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: CNTA

Analyst Forecast

According to 7 analysts, the average rating for CNTA stock is "Buy." The 12-month stock price forecast is $10.0, which is an increase of 11.98% from the latest price.

Price Target

$10.0

(11.98% upside)

Analyst Consensus: Buy